Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Published trial adds weight to Takeda's confidence in next-generation antidiabetic

This article was originally published in Scrip

Executive Summary

The first full results to be published from a Phase II trial with Takeda's first-in-class oral antidiabetic TAK-875 confirm both efficacy benefits for the GPR40 agonist and a significantly lower incidence of hypoglycaemia compared with the sulphonylurea glimepiride.



Related Companies